Gastroesophageal-junction Cancer Clinical Trials

10 recruiting

Gastroesophageal-junction Cancer Trials at a Glance

12 actively recruiting trials for gastroesophageal-junction cancer are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Houston, New York, and Nashville. Lead sponsors running gastroesophageal-junction cancer studies include Fudan University, Hallym University Medical Center, and Eikon Therapeutics.

Browse gastroesophageal-junction cancer trials by phase

Treatments under study

About Gastroesophageal-junction Cancer Clinical Trials

Looking for clinical trials for Gastroesophageal-junction Cancer? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastroesophageal-junction Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastroesophageal-junction Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 1Phase 2

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Endometrial CancerAdvanced Solid TumorsMSI-H or dMMR Advanced Solid Tumors+4 more
Eikon Therapeutics160 enrolled10 locationsNCT07262619
Recruiting
Phase 1

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Breast CancerEsophageal CancerGastric Cancer+7 more
SystImmune Inc.280 enrolled17 locationsNCT06293898
Recruiting
Phase 3

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Gastric CancerGastroesophageal-junction CancerHER2-positive Gastric Cancer+1 more
Shanghai Henlius Biotech550 enrolled208 locationsNCT06532006
Recruiting
Phase 1

IKS014 in Advanced Solid Tumors That Express HER2

Breast CancerGastric CancerGastroesophageal-junction Cancer
Iksuda Therapeutics Ltd.165 enrolled12 locationsNCT05872295
Recruiting
Phase 2

A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer

Gastric CancerGastroesophageal-junction Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.200 enrolled2 locationsNCT07110571
Recruiting
Phase 2

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

Locally Advanced Gastric AdenocarcinomaMSI-H/dMMR Gastric CancerMSI-H/dMMR Gastroesophageal-junction Cancer
Royal Marsden NHS Foundation Trust50 enrolled9 locationsNCT06250036
Recruiting

Registry for Esophageal and Gastroesophageal Junction Cancer

Esophageal CancerGastroesophageal-junction Cancer
Memorial Sloan Kettering Cancer Center50 enrolled1 locationNCT06558786
Recruiting
Not Applicable

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

Esophageal CancerGastric CancerGastroesophageal-junction Cancer+1 more
University of California, Davis300 enrolled1 locationNCT06101277
Recruiting
Phase 2

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

Gastroesophageal-junction CancerGastroesophageal Junction AdenocarcinomaMetastatic Cancer+6 more
Fudan University55 enrolled1 locationNCT06121700
Recruiting
Phase 2

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

Gastric CancerGastroesophageal-junction CancerCarcinoma+4 more
The First Affiliated Hospital with Nanjing Medical University80 enrolled1 locationNCT05494060
Recruiting
Phase 2

Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

Gastric CancerGastroesophageal-junction Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School140 enrolled3 locationsNCT05687357
Recruiting
Phase 1Phase 2

Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma

Gastric CancerGastroesophageal-junction Cancer
Hallym University Medical Center42 enrolled1 locationNCT05439993